Anonymous (2026). Efficacy and Safety of Prasugrel, Ticagrelor, or Clopidogrel After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.. JAMA cardiology.
Anonymous. Efficacy and Safety of Prasugrel, Ticagrelor, or Clopidogrel After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.. JAMA cardiology. 2026; PMID: 42201709
Anonymous. Efficacy and Safety of Prasugrel, Ticagrelor, or Clopidogrel After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.[J]. JAMA cardiology. 2026.
@article{paper2026,
author = {Anonymous},
title = {Efficacy and Safety of Prasugrel, Ticagrelor, or Clopidogrel After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.},
journal = {JAMA cardiology},
year = {2026},
note = {PMID: 42201709},
}
TY - JOUR AU - Anonymous TI - Efficacy and Safety of Prasugrel, Ticagrelor, or Clopidogrel After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. T2 - JAMA cardiology PY - 2026 AN - PMID:42201709 ER -
The relative efficacy and safety of oral P2Y purinergic receptor 12 (P2Y12) inhibitors (clopidogrel, ticagrelor, or prasugrel) after percutaneous coronary intervention (PCI) are not well defined.